

REMARKS

Claims 1-11, 14, 17 and 22-24 are currently pending in this application. Claims 12-13, 15-16, 18-21, and 25 are canceled herein. Claim 1 is amended herein to correct a spelling error. Claims 22, 23 and 24 are amended herein to correct grammatical errors. No claims are added herein.

Paragraph [0012] of the originally filed Specification has been amended to correct a spelling error as well.

Applicants respectfully submit that the pending claims of this application are in condition for allowance, and that this case is now in condition for allowance of all claims therein. Thus, entrance of the amendments and consideration of the arguments is respectfully requested. If the Examiner disagrees, or believes for any other reason that direct contact with Applicant's attorney would advance the prosecution of the case to finality, the Examiner is invited to telephone the undersigned at the number given below.

No fee is deemed necessary in connection with the filing of this Reply and Amendment. However, the Commissioner is authorized to charge any fee which may now or hereafter be due for this application to GTC Biotherapeutics' Deposit Account No. 502092.

Early and favorable action is earnestly solicited.

Dated: 12/14/05

Respectfully submitted,

By: 

Byron V. Olsen, Reg. No. 42,960
Attorney for Applicant
GTC Biotherapeutics, Inc.
175 Crossing Blvd., Suite 410
Framingham, MA 01702
Tel. #(508) 370-5150
Fax #(508) 370-3797